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Abstract
Herpes Zoster is a viral illness caused by reactivation of the varicella-zoster virus within
the human body resulting in the subsequent infection. Herpes Zoster is characterized by a painful
vesicular rash which follows the dermatomal distribution pattern due to the viral activation of the
underlying nerves. One of the most common and debilitating complications of Herpes Zoster is
postherpetic neuralgia. Postherpetic neuralgia is defined as pain that persists following cessation
of the rash for greater than 90 days. This literature review will focus on ways the acute phase of
Herpes Zoster can be managed in order to reduce the incidence of postherpetic neuralgia.
The literature review of the above topic was based upon the successful completion of an
objective structured clinical examination. Included in this report is the written case study from
that examination which is based on a 70-year-old female patient who is diagnosed with Herpes
Zoster. A research of the related literature was conducted using the PubMed and Cochrane
databases with the keywords for the search used being ‘postherpetic neuralgia prevention’.
Restrictions for publication date were limited to 2011-2020 with a focus placed on the evaluation
in the elderly population. The literature analyzed found many common treatment modalities have
been shown to have no effect on postherpetic neuralgia reduction, and more studies are needed in
order to further analyze more invasive pain management techniques as well as timing of pain
management initiation.
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Prevention of Post-Herpetic Neuralgia in Patients with Herpes Zoster Infection
Herpes Zoster is a viral illness commonly referred to as shingles. It results from varicellazoster virus, the same virus that causes chickenpox, that becomes reactivated from its latent form
in the human body resulting in the subsequent infection. There are approximately 1 million cases
of Herpes Zoster that occur annually with roughly 30% of Americans being affected over their
lifetime (Saguil, Kane, & Mercado, 2017). One of the biggest risk factors for contracting Herpes
Zoster is age. As age increases, the body’s T lymphocyte-specific immunity to the varicellazoster virus decreases, leaving unvaccinated elderly patients at the greatest risk as well as
immunocompromised patients (Saguil, Kane, & Mercado, 2017). The reduction of immunity
allows the virus to multiply in the ganglia which leads to the retrograde transport along the
nerves which then produces the pain and dermatologic presentation of herpes zoster (Makharita,
2017). Clinical presentation for herpes zoster includes a vesicular rash with hypersensitivity and
pain often preceding eruption of the rash (Kennedy-Malone, Martin-Plank, & Duffy, 2019).
Patients may also experience secondary symptoms including generalized malaise, anxiety,
headache, fever, and other symptoms. Diagnosis is most often made by physical presentation and
exam alone, but polymerase chain reaction (PCR) can be used in complex or abnormally
presenting cases (Kennedy-Malone et al., 2019). Treatment includes pain control as well as
antiviral therapy to slow replication of the virus, stop the formation of new lesions, and prevent
ocular complications (Le & Rotheberg, 2020). Antiviral therapy is most effective if started in the
first 72 hours of rash eruption and there is a relationship between acute pain being diminished at
a faster rate if antiviral therapy is started within that time frame (Chen et al., 2014). The main
form of prevention against individuals contracting Herpes Zoster is vaccination. The newest and
most effective vaccination for prevention of Herpes Zoster is known as Shingrex and has been
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found to reduce cases by 97% (Le & Rotheberg, 2020). It is approved for adults 50 years of age
and older and is a 2-dose vaccination with the second administration given 2-6 months following
the first dose (Le & Rotheberg, 2020).
One of the most common and debilitating complications of Herpes zoster is post-herpetic
neuralgia. Postherpetic neuralgia occurs in roughly 20% of patients with Herpes zoster and 80%
of postherpetic neuralgia cases occur in patients 50 years of age and older. Postherpetic neuralgia
is defined as pain that follows the dermatomal distribution and is present for at least 90 days
following cessation of the rash (Saugil et al., 2017). As the virus replicates within the nerve
during a Herpes Zoster outbreak, this often causes an inflammatory response and subsequent
damage to the nerve therefore causing the pain and negative effects of postherpetic neuralgia
(Saugil et al., 2017). The pain caused by postherpetic neuralgia is often described as sharp,
burning, and debilitating by patients and for many the pain is non-refractory to treatment and has
the potential to persist for years (Nakamura et al., 2017). Current treatment options for patients
suffering from postherpetic neuralgia include acetaminophen, NSAIDS, topical capsaicin or
lidocaine, or weak opioids for mild pain and stronger opioids, gabapentin, amitriptyline, or
anticonvulsants for moderate-severe pain (Le & Rotheberg, 2020). As expected, postherpetic
neuralgia has negative effects on quality of life for patients as well as being costly. A study based
in Japan was able to conclude that Herpes Zoster has a substantial financial burden on the
healthcare system as a result of high costs related directly to clinic visits, prescriptions and OTC
medications, and hospitalizations. It was also found that both societal and healthcare payer costs
were substantially higher in those individuals who suffered from postherpetic neuralgia (Nakamura,
2017). Postherpetic neuralgia has negative effects on patient’s physically, socially, functionally, and
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psychologically, making preventing this complication something that should be made a priority for
all patients.

The purpose of this report is to gain insight into both prevention and management of one
of the most common complications of Herpes Zoster, post-herpetic neuralgia. Included in this
paper is a case report of a 70-year-old female who was diagnosed with Herpes Zoster. While this
was the initial evaluation of the patient and post-herpetic neuralgia was not identified, she is at
higher risk of this occurring due to her age as well as immunocompromised status with a history
of rheumatoid arthritis. This is also discussed as a need for follow-up and education was
provided in order to further assess for complications including postherpetic neuralgia and
emergencies such as herpes opthamalicus as well as to evaluate at that time for cessation of the
rash and adequate pain management.
Case Report
A 70-year old female presented to the clinic with a chief complaint of right-sided low
back pain for 2 days. She denied any trauma to the area or change in activity level that brought
on the pain. She rated the pain 6/10 which was aggravated by movement and touch and relieved
with ice to the area. She described the pain as sharp and burning and non-radiating in nature. She
denied any numbness or tingling as well. Upon presentation to the clinic, she was afebrile with a
mildly elevated blood pressure at 154/90. All other vital signs were stable. Her past medical
history includes hypertension and rheumatoid arthritis. She takes 20mg Lisinopril daily as well
as prednisone PRN, which she reported to taking daily at this time. She has also been taking
PRN Tylenol for her back pain and this has been ineffective. No other relevant family, surgical,
or social history was reported. She reported no history of previous back pain episodes similar to
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this one, no numbness or tingling down the affected leg, she denied any bowel or bladder
dysfunction, and she denied any genitourinary symptoms including dysuria, suprapubic
tenderness, frequency, urgency, CVA tenderness and other concerns. She reports she did receive
a flu vaccination this season but denies receiving the Shingrex or Zostavax vaccinations for
shingles in the past. All other vaccinations were reported as up to date. Upon examination, her
lower right-lumbar region is tender with palpation and this pain does not radiate. There is no
bony tenderness along the cervical, thoracic, or lumbar spine. There is no CVA tenderness. Upon
examination of the skin, a roughly 7.5cm oblong erythematous lesion with fluid-filled blisters
was visualized to the right lower back. No other lesions visualized as the lesion did not cross the
midline along with following a pattern along the T12/L1 dermatome. Patient reports she was
unaware of a rash or blisters to that region and is not sure how long it has been there. The
remainder of the exam was unremarkable.
Diagnosis of Herpes Zoster was discussed with the patient based on the findings from the
physical assessment. Different treatment modalities and antiviral therapy were presented as well,
and it was agreed upon to treat with valacyclovir 1000mg PO Q8h for 7 days as opposed to
acyclovir which requires dosing 5 times a day for 7 days (Le & Rotheberg, 2020). The patient
was also advised to trial topical therapy modalities including lidocaine 5% patches for the pain
and to continue with ice as this was effective as well as Tylenol PRN. The patient was advised
that she will be contagious as long as the blisters are present, and she will stop being contagious
once they have crusted over. She was advised to keep area covered during the contagious period
and avoid having others come in direct contact with the affected area and specifically the
vesicular fluid. Things such as dressings and clothing that may come into contact with the fluid
should be handled with caution. Education was provided on monitoring area for any spreading
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and potential serious complications including any lesions that present to the face especially near
the eyes requiring immediate medical attention. If this were to occur, she was advised to seek
immediate care at the nearest emergency room. Follow-up was scheduled in one weeks' time for
reassessment of pain control, potential for postherpetic neuralgia, and to ensure improvement of
rash with no new eruptions. The patient verbalized understanding of the above recommendations.
Her mildly elevated blood pressure was not addressed and at this point attributed to her 6/10 pain
and would be reevaluated at her next visit as well.
Literature Review
This literature review is focused on the effectiveness of pain management strategies and
different modalities to prevent the complication of post-herpetic neuralgia in patients following
Herpes Zoster infection. There are currently a wide range of agents, both non-invasive and
invasive, used for the treatment of postherpetic neuralgia as well as the acute pain present with
Herpes Zoster infection. The question brought about by this literature review and the studies
mentioned is are any modalities or combination of treatment options that are more effective in
reducing the incidence of postherpetic neuralgia?
Pain Management Techniques
Corticosteroids. Corticosteroids are effective in a wide range of conditions for assistance
with reduction of inflammation and subsequent relief of pain. The hypothesis regarding this
medication is that its use in the acute phase of Herpes Zoster infection can help in reducing the
inflammation and subsequent nerve damage that leads to postherpetic neuralgia. According to
the American Family Physician, both prednisolone and prednisone are effective adjunctive
therapy for Herpes Zoster and are associated with a reduction in healing time of lesions as well
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as reduction in pain, but have no effect on the prevention of postherpetic neuralgia (Saugil et al.,
2017). This is further supported by the 2013 Cochrane Review based on a moderate quality of
evidence (Han et al., 2013) as well as a 2019 review showing no benefit in postherpetic neuralgia
prevention (Kowalsky & Wolfson, 2019b). While corticosteroids may be an effective choice for
some patients during the acute phase of Herpes Zoster, there use has not been shown to decrease
the incidence of postherpetic neuralgia.
Invasive therapies. Invasive pain management techniques encompass both
intracutaneous injections and subcutaneous injections with an analgesic agent as well as a
steroid. These therapies are utilized for severe pain during the acute phase of Herpes Zoster
infections as well as for pain that does not respond to typical treatment modalities for patients
already suffering from postherpetic neuralgia. A 2017 randomized clinical trial looked at the
efficacy of subcutaneous injections of triamcinolone and lidocaine and found a statistically
significant reduction in neuropathic pain at both 3 and 6 months after rash eruption when
compared to the control group (Ni et al., 2017). An additional study looked at single cutaneous
injections of ropivacaine and methylprednisone within 14 days of rash eruption in addition to the
antiviral therapy of acolyovir and pregabalin as well as PRN Tylenol for breakthrough pain. This
treatment protocol led to statistically significant lowered pain intensity and duration, and
decreased time to rash clearance as opposed to the control group. The researchers however were
unable to formally conclude that the incidence of postherpetic neuralgia was decreased, only
suggesting that this may occur and that more studies are needed (Cui et al., 2018). While these
single studies do show promise in invasive pain management techniques in preventing
postherpetic neuralgia, more studies are needed to determine their true effectiveness. Cost-
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effectiveness as well as potential for increased complications and must be considered with the
above strategies as well as more invasive ones.
Anticonvulsants. Gabapentin is the most commonly used anticonvulsant as a treatment
for the neuropathic pain in Herpes Zoster. Gabapentin is also frequently used to treat chronic
neuropathic pain in adults with a wide array of conditions including diabetic neuropathy and
fibromyalgia. It is also used as an anticonvulsant for a variety of seizure disorders and
neurological disorders. Researchers hypothesized that the prevention of central sensitization and
antihypersensitivity actions in dorsal horn neurons during the acute phase of Herpes Zoster may
help to prevent postherpetic neuralgia (Rullan et al., 2017). The results however are not
consistent with this hypothesis with majority showing no effectiveness in the prevention of
postherpetic neuralgia at a wide variety of doses and titrating strategies (Bulilete et al., 2019).
While this medication has been shown to be effective in pain reduction and is a well-established
option (Rullan et al., 2017), current evidence shows that the addition of gabapentin as a treatment
modality for the acute pain of Herpes Zoster has not been shown to reduce the incidence or
prevent postherpetic neuralgia.
Timing of Pain Management Initiation
Pain management is an important aspect of Herpes Zoster treatment. While antiviral
therapy initiation has been regarded as a time-sensitive component with increased effectiveness
noted when administered within the first 72 hours of rash eruption (Kennedy-Malone, MartinPlank, & Duffy, 2019), there are currently no guidelines regarding initiation of pain
management. Pain is a completely subjective experience for the patient and varies with each case
and situation. Recent studies have been able to show a correlation between timing of pain
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management initiation and incidence of postherpetic neuralgia. A study by Xing, Sun, & Yan
(2020) was able to show that in elderly patients with moderate-severe Herpes-associated pain,
when pain management strategies were initiated and controlled within the first 2 weeks of rash
onset that postherpetic neuralgia incidence was decreased. The researchers hypothesized that by
providing adequate pain control in the acute period, central hyperexcitability would be reduced
in the initiation period and allow normal central processing to not be damaged by subsequent
factors (Xing et al., 2020). A 2017 meta-analysis looking at 9 different RCTs and the timing of
pain management supplementation was able to support this finding showing a statistically
significant decrease in the incidence of postherpetic neuralgia with early pain management
(Xing, Zhou, Zhang, & Yan, 2017). Even with these findings, more quality studies are needed to
further support this conclusion and allow it to be applied to practice.
Antiviral Therapy
Antiviral therapy is an important component of Herpes Zoster treatment, especially in
those high-risk populations such as the elderly or those who are immunocompromised. It has
been shown that antiviral therapy such as acyclovir, famciclovir, and valacyclovir when started
within the first 72 hour of rash eruption are effective in reducing the acute pain associated with
Herpes Zoster (Kennedy-Malone, Martin-Plank, & Duffy, 2019). It is hypothesized by
researchers that reducing the viral load and viral replication during the acute phase of Herpes
Zoster would reduce the incidence and prevent postherpetic neuralgia due to the reduced damage
caused by the virus to the underlying nerves. According to the 2014 Cochrane Review,
researchers were able to conclude based on high quality of evidence that oral acyclovir did not
significantly prevent postherpetic neuralgia and more research is needed on the effectiveness of
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postherpetic neuralgia prevention with both famciclovir and valacyclovir (Chen et al., 2014).
This was further supported by the 2019 review again showing no benefit in preventing
postherpetic neuralgia with the use of any form of antiviral therapy (Kowalsky, Wolfson, &
Zehtabchi, 2019a).
Vaccinations
There are currently two vaccinations available for the prevention of Herpes Zoster; the
live attenuated vaccine Zostavax and recombinant vaccine Shingrex (CDC, 2018). Zostavax was
first offered in 2006 and Shingrex was first offered in 2017. Shingrex is offered as a 2-vaccine
series and has become the preferred vaccine choice since becoming available to the public due to
its increased effectiveness (CDC, 2018). Even if an individual has been previously vaccinated
with Zostavax, the Shingrex series is recommended. Shingrex has been found to be 97%
effective in preventing Herpes Zoster and 91% effective in preventing postherpetic neuralgia in
adults 50-69 years of age and 91% effective in preventing Herpes Zoster and 89% effective in
preventing postherpetic neuralgia adults 70 years of age and older (CDC, 2018). A 2011
Cochrane review found that there was insufficient evidence to show a direct correlation between
vaccination (Zostavax) and postherpetic neuralgia reduction beyond its effect in the reduction of
Herpes Zoster (Chen et al., 2011). Even with the Cochrane Review showing no direct correlation
with Zostavax vaccination and postherpetic neuralgia reduction, data from the CDC supports the
claim that Shingrex vaccination does aid in postherpetic neuralgia prevention. There is currently
no updated Cochrane review assessing the potential for postherpetic neuralgia incidence
reduction with the Shingrex vaccination, but data from the CDC does support this correlation.

PREVENTION OF POSTHERPETIC NEURALGIA

13

Learning Points
•

Herpes zoster and the complication of postherpetic neuralgia can have debilitating
effects on patients’ physically, socially, and psychologically as well as being
costly for the healthcare system and patient.

•

Corticosteroid use, antiviral therapy, and gabapentin use during the acute phase of
Herpes Zoster outbreak was found to be ineffective in reducing postherpetic
neuralgia incidence.

•

The most effective and reliable way to prevent postherpetic neuralgia is to prevent
Herpes Zoster by vaccination with the 2-dose vaccination series of Shingrex.

•

Invasive pain management techniques and the timing of pain management
initiation both show promise in postherpetic neuralgia prevention, but more
studies are needed in order to confirm or deny efficacy.

PREVENTION OF POSTHERPETIC NEURALGIA

14

References
Bulilete, O., Leiva, A., Rullan, M., Roca, A., & Llobera, J. (2019). Efficacy of gabapentin for the
prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind,
randomized controlled trial. PLoS ONE, 14(6), e0217335.
doi:10.1371/journal.pone.0217335
Centers for Disease Control [CDC]. (2018). Shingles Vaccination. Retrieved from
https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix/index.html
Chen, N., Li, Q., Yang, J., Zhou, M., & He, L. (2014). Antiviral treatment for preventing
postherpetic neuralgia. Cochrane Systematic Review-Intervention. Retrieved from
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006866.pub3/full
Chen, N., Li, Q., Zhang, Y., Zhou, M., Zhou, D., & He, L. (2011). Vaccination for preventing
postherpetic neuralgia. Cochrane Systematic Review- Intervention. Retrieved from
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007795.pub2/full
Cui, J., Zhang, J., Yan, F., Yang, X., Wang, X., Zhao, Z., . . . Geng, Z. (2018). Effect of single
intra-cutaneous injection for acute thoracic herpes zoster and incidence of postherpetic
neuralgia. Pain Management Nursing, 19(2), 186-194. doi:10.1016/j.pmn.2017.09.002
Han, Y., Zhang, J., Chen, N., He, L., Zhou, M., Zhou, C. (2013). Corticosteroids for preventing
postherpetic neuralgia. Cochrane Systematic Review. Retrieved from
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005582.pub4/full?highligh
tAbstract=neuralgi%7Cneuralgia%7Cpost%7Cherpetic%7Cherpet

PREVENTION OF POSTHERPETIC NEURALGIA

15

Kennedy-Malone, L., Martin-Plank, L., & Duffy, E.G. (2019). Advanced Practice Nursing in the
care of Older Adults (2nd ed.). F.A. Davis Company: Philadelphia, PA.
Kowalsky, D. S., Wolfson, A. B., & Zehtabchi, S. (2019a). Antiviral medications for the
prevention of postherpetic neuralgia after herpes zoster infection. Academic Emergency
Medicine, 26(6), 684-685. doi:10.1111/acem.13662
Kowalsky, D. S., Wolfson, A. B., & Zehtabchi, S. (2019b). Corticosteroids for preventing
postherpetic neuralgia after herpes zoster infection. Academic Emergency Medicine, 26(6),
686-687. doi:10.1111/acem.13661
Le, P., & Rotheberg, M. (2020). Herpes zoster infection. Epocrates, Inc. Retrieved from
https://online.epocrates.com/diseases/23/Herpes-zoster-infection
Makharita, M.Y. (2017). Prevention of Post-herpetic Neuralgia from Dream to Reality: A Tenstep Model. Pain Physician, 20:E209-E220 Retrieved from
https://www.painphysicianjournal.com/current/pdf?article=NDExMA==&journal=102
Nakamura, H., Mizukami, A., Adachi, K., Matthews, S., Holl, K., Asano, K., … & Curran, D.
(2017). Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60
Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study
in Kushiro, Japan. Drugs Real World Outcomes, 4(4). Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684048/
Ni, J., Wang, X., Tang, Y., Yang, L., Zeng, Y., & Guo, Y. (2017). Subcutaneous injection of
triamcinolone and lidocaine to prevent postherpetic neuralgia. Pain Physician, 20(5), 397.
Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28727702

PREVENTION OF POSTHERPETIC NEURALGIA

16

Rullan, M., Bulilete, O., Leiva, A., Soler, A., Roca, A., Gonzalez-Balz, M.J., Lorente, P.,
Llobera, J., & postherpetic neuralgia Group. (2017). Efficacy of gabapentin for prevention
of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. Trials.
doi: 10.1186/s13063-016-1729-y
Saguil, A., Kane, S., Mercado, M., & Lauters, R. (2017). Herpes zoster and postherpetic
neuralgia: Prevention and management. American Family Physician, 96(10), 656. Retrieved
from https://www.ncbi.nlm.nih.gov/pubmed/29431387
Xing, X., Sun, K., & Yan, M. (2020). Delayed initiation of supplemental pain management is
associated with postherpetic neuralgia: A retrospective study. Pain Physician, 23(1), 65.
Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/32013280
Xing, X., Zhou, Z., Zhang, F., & Yan, M. (2017). The effect of early use of supplemental therapy
on preventing postherpetic neuralgia: A systematic review and meta-analysis. Pain
Physician, 20(6), 471. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28934778

